Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Can-Fite BioPharma (CANF) announced that the first 247 patients completed dosing in its pivotal Phase III Piclidenoson trial for moderate-to-severe plaque psoriasis. The company expects the independent data monitoring committee to report interim efficacy and safety results in Q1 2027.
The randomized, double-blind trial is being run under a protocol agreed with the FDA and EMA. Patients take either 3 mg of Piclidenoson or a placebo by mouth twice daily. The trial has two primary measures of effectiveness at Week 16: the share of patients with at least a 75% improvement on the Psoriasis Area and Severity Index and the share with a physician assessment score of 0 or 1, meaning clear or almost clear skin. The Piclidenoson development program includes safety data from more than 1,500 subjects.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointPhase III dosing is complete for the first 247 patients in the Piclidenoson interim-analysis group
- Minor pointPhase III trial protocol was agreed with both the FDA and EMA
- Minor point. Forward-looking: it has not happened yet and may not happen.Interim efficacy and safety results are expected from the independent data monitoring committee in Q1 2027
Negative
- None.
Key Figures
- Patients completed treatment
- 247 patients
- Pivotal Phase III psoriasis study interim-analysis cohort
- Interim analysis timing
- Q1 2027
- Results expected from the pre-specified interim analysis
- Study dose
- 3 mg twice daily
- Piclidenoson administered orally
- Co-primary endpoint timing
- Week 16
- PASI 75 and sPGA efficacy endpoints
- PASI 75 threshold
- At least 75% improvement
- Psoriasis Area and Severity Index
- sPGA score
- 0 or 1
- Clear or almost clear skin
Previous Clinical trial Reports
-
Piclidenoson was already in Phase III psoriasis development under FDA/EMA regulatory frameworks.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pasi 75 medical
idmc medical
double-blind medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The study evaluates oral Piclidenoson and last patient in the interim-analysis cohort completes treatment
Ramat Gan, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced completion of treatment of the first 247 patients in its pivotal Phase III study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis.
The company announced that the last patient in the interim-analysis cohort of its pivotal Phase III psoriasis study received the final dose of study treatment. Results of the pre-specified interim analysis are expected to be read out by the Independent Data Monitoring Committee (IDMC) in Q1 2027.
Completion of dosing marks a key milestone toward the interim analysis, which will evaluate the efficacy and safety of Piclidenoson in patients with moderate-to-severe plaque psoriasis. The Company previously announced completion of enrolment of the first 247 patients for this analysis.
Piclidenoson is an investigational, orally administered A3 adenosine receptor agonist that targets inflammatory pathways implicated in psoriasis. Its clinical development program includes a safety database involving more than 1,500 subjects. If successfully developed and approved, Piclidenoson could offer a unique oral treatment option for patients requiring long-term management of their disease, with a favorable safety profile that supports chronically administered.
The randomized, double-blind, placebo-controlled study is being conducted under a protocol agreed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Patients receive Piclidenoson 3 mg or placebo orally twice daily. The co-primary efficacy endpoints at Week 16 are the proportion of patients achieving at least a
“Completion of dosing in the interim-analysis cohort brings us an important step closer to the anticipated results from our pivotal Phase III psoriasis study,” said Motti Farbstein, Chief Executive Officer of Can-Fite. “We believe Piclidenoson’s oral administration, selective mechanism of action, and favourable safety profile observed in clinical studies support its potential as a convenient long-term treatment option for patients with psoriasis. We look forward to reporting the interim results in Q1 2027.”
About Piclidenoson
Piclidenoson is an orally bioavailable, highly selective A3 adenosine receptor agonist with anti-inflammatory activity demonstrated in both preclinical and clinical studies. The drug has accumulated an extensive clinical safety database involving more than 1,500 subjects and is being developed as a potential chronic therapy for psoriasis and other inflammatory diseases. The drug’s mechanism of action entails inhibition of the inflammatory cytokines interleukin 17 and 23 (IL-17 and IL-23) and the induction of apoptosis of patients’ skin cell keratinocytes involved with the disease pathogenicity.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson, is being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of 2027. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,700 patients in clinical studies to date. For more information please visit: www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, the development of Piclidenoson, the timing and results of the planned interim analysis of the Phase III psoriasis study, the safety, efficacy and therapeutic potential of Piclidenoson, and the potential for Piclidenoson to receive regulatory approval and be commercialized. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact:
Motti Farbstein
+972-3-9241114
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.